Northern blotting confirmed previous results indicating that the mitogen-activated protein kinase (MAPK) phosphatase Pyst2-L was highly expressed in leukocytes obtained from acute myeloid leukemia (AML) patients. High levels of Pyst2-L mRNA were expressed in bone marrow (BM) and peripheral leukocytes from nine AML and acute lymphoblastic leukemia (ALL) patients. BM from healthy individuals expressed very low levels of Pyst2-L. Whereas high levels of Pyst2-L mRNA and protein were detected in several leukemia cell lines, Pyst2-L mRNA was detected neither in 33/34 samples of normal peripheral blood mononuclear cells (PBMC) nor in leukocyte fractions enriched with CD34 þ cells. Certain solid tumor and lymphoblastoid cell lines expressed high levels of Pyst2-L mRNA. In view of the association of Pyst2-L to MAPK signaling cascades, we tested if cell activation, a process involving MAPK signaling, influences Pyst2-L expression. Indeed, activation of T cells and endothelial cells increased Pyst2-L in these cells. Furthermore, TPA, a known MAPK activator, induces the expression of both Pyst2-L mRNA as well as the Pyst2-L protein in leukemia cells. This induction was partially inhibited by PD098059, an Mek1/2-specific inhibitor. Based on the results of this and previous studies, we hypothesize that the high levels of Pyst2-L detected in the active state of AML and ALL diseases and in other types of cancer reflect an altered MAPK signaling pathway in such malignant processes. This alteration may be the result of a failed attempt to counter the constitutive activation of MAPK in transformed cells or alternatively, may represent the activated state of such cells.
Introduction
Pyst2 (also known as MKP-X) is a member of the Pyst subfamily of dual-specificity phosphatases (DUSPs) (Groom et al., 1996; Muda et al., 1997; Shin et al., 1997; Dowd et al., 1998) . It is highly homologous, both at the DNA as well as at the protein level, with the other two group members (Pyst1 and Pyst3) (Groom et al., 1996; Dowd et al., 1998; Dickinson et al., 2002; Theodosiou and Ashworth, 2002) . Phosphatases including Pyst2 play an important role in various signaling pathways and as such control essential cellular functions and phenotypic characteristics (Frearson and Alexander, 1996; Muda et al., 1997; Berndt, 1999) . Among such signaling pathways is the well-characterized mitogenactivated protein kinase (MAPK). Indeed, the predominantly cytosolic Pyst2 protein is showing substrate selectivity for the classical p42 (ERK2) isoform of MAPK (Shin et al., 1997; Dowd et al., 1998) .
The regulatory functions of MAPK are mediated by phosphorylation of specific target molecules (such as transcription factors and other kinases) found in cell membranes, cytoplasm and nucleus (Marshall, 1994a, b; Seger and Krebs, 1995) . The MAPKs are activated by phosphorylation of both threonine and tyrosine residues. Dephosphorylation of either one of these residues is sufficient to suppress the activity of the kinase. Dephosphorylation is mediated by several phosphatases including DUSPs. The balance between kinases and phosphatases (Berndt, 1999; Biethahn et al., 1999; Saxena and Mustelin, 2000; Ballif and Blenis, 2001 ) as well as other mechanisms (Keyse and Ginsburg, 1993) regulate the activation of the MAPK family members. Dysregulation of the Ras/Raf/MEK/ERK pathway plays a major role in cancer pathogenesis and has been associated with a multitude of pathological conditions, including oncogenic transformation and tumorigenesis (Klint et al., 1999; Sebolt-Leopold, 2000; Lee and McCubrey, 2002) .
Using a gene expression array, we (Levy-Nissenbaum et al., 2003a) showed that the Pyst2 (GenBank accession no. X93921) is highly expressed in leukocytes derived from acute myeloid leukemia (AML) patients. By using the 5 0 -RNA ligation-mediated rapid amplification of cDNA ends (5 0 -RLM-RACE) technique, we recently sequenced the remaining, unsequenced 5 0 -regions of the Pyst2 transcript (designated as PYST2-L, GenBank accession no. AF508727) (Levy-Nissenbaum et al., 2003c) . Further studies utilizing RT-PCR, verified and extended the microarray findings (Levy-Nissenbaum et al., 2003b) .
The information about the Pyst2-L gene is rather scarce and its association with myeloid leukemia (ML) and other malignancies was never documented. We therefore determined, in the present study, the Pyst2-L expression profile in various malignant and normal cells as well as its expression under various physiological conditions. Using Northern blot analysis, we quantitatively determined the expression of Pyst2-L in leukocytes of AML and acute lymphoblastic leukemia (ALL) patients at the stage of active disease, in leukocytes from healthy individuals enriched for myeloid cells or for cells expressing the progenitor-cell marker CD34 and in ML and other cancer cell lines. It was demonstrated that the expression of Pyst2-L in malignant or normal cells was upregulated by outside-in activation or differentiation signals, which involve the MAPK pathway. Some of these results were confirmed at the protein level.
Materials and methods

Cell cultures
The THP-1, HL-60, CHRF, K562, Meg01, KG-1, T47D, MCF7 and HT29 cell lines were previously described Levy-Nissenbaum et al., 2002 , 2003b . Human myeloid leukemia cell lines (Dami and U937) were provided by the Hematology Institute, Tel-Aviv Sourasky Medical Center, Israel. The B lymphoma cell line (Daudi) was kindly provided by Dr Rachel Ehrlich, the T-cell lymphoma cell line (Jurkat) was kindly provided by Dr Niza Frenkel, the ML cell line PLB680 was kindly provided by Dr Irit Aviram, the prostate cell lines (DU147, 22RV and LNCAP) were kindly provided by Dr Nava Zisapel and the breast cancer cell lines (HBL100 and MB231) were kindly provided by Dr Iafa Keydar. All the above scientists are at Tel-Aviv University, Tel Aviv, Israel. The melanoma cell lines (GT and RK) and the three different lymphoblastoid B-cell lines were kindly provided by Dr Michael Micksche, Vienna University, Vienna, Austria. The Hodgkin's lymphoma cell lines (L428 and KM42) were kindly provided by Dr Jacob Gopas, Ben-Gurion University, Beer-Sheba, Israel. The KBM5 cell line was kindly provided from Dr Dina Ben-Yehuda's lab, Hadassa University Hospital, Jerusalem, Israel. The colon cancer cell lines (0467, 1100, 1203, 427) were kindly provided by Dr Donald Morton, The John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA. The U937, Daudi, Jurkat, PLB680, KBM5, SW480 and the lymphoblastoid B-cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 100 U/ml streptomycin, 12.5 U/ml nystatin, 100 U/ml penicillin, 2 mm l-glutamine. The Dami cell line was maintained in Iscove's medium supplemented with 10% FCS, 100 U/ml streptomycin, 12.5 U/ml nystatin, 100 U/ ml penicillin and 2 mm l-glutamine. The SW620 cell line was maintained in Leibovitz L-15 medium supplemented with 15% FCS, 100 U/ml streptomycin, 12.5 U/ml nystatin, 100 U/ml penicillin, 0.075% sodium bicarbonate, 10 mm HEPES buffer and 2 mm l-glutamine.
Isolation of BM leukocytes and PBMC
Bone marrow (BM) aspirations were obtained under local anesthesia from the posterior superior iliac spine of patients. Peripheral blood mononuclear cells (PBMC) from leukemia patients and from healthy blood bank donors were isolated by Ficoll-Hypaque. The clinical characteristics of the leukemia patients and the cell isolation procedures have been previously described in detail (Levy-Nissenbaum et al., 2003a, b) .
Isolation of normal human CD34
þ cells CD34 þ cells were isolated from cord blood by positive selection on LS þ Magnetic separation columns using a CD34 þ cell enrichment cocktail (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's protocol.
Isolation and activation of normal human T cells
Human T cells were isolated from PBMC by negative selection on LS þ magnetic separation columns using a T-cell enrichment cocktail (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's protocol. Standard activation procedures (Wagers et al., 1998) were utilized. Briefly, T cells were activated by incubating these cells in 24-well plates precoated overnight at 41C with anti-CD3 and anti-CD28 mAbs (Ancell, Co., Bayport, MN, USA) (Eshel et al., 2000) .
Isolation and activation of human umbilical cord vein endothelial cells (HUVEC)
HUVEC were isolated from umbilical cord veins according to the method of Jaffe et al. (1973) as previously described (Eshel et al., 2000) . Primary cultures were serially passaged, and passages two and three were taken for experiments. HUVEC 2 Â 10 5 in volume of 300 ml were plated in a 24-well plate and incubated for 4 h in serum-free medium or with IL-1b (100 U/ ml) and TNF-a (100 U/ml). The IL-1b and the TNF-a were purchased from Endogen Inc. (Woburn, MA, USA). CD62E was used as an activation marker (Eshel et al., 2000) .
Total RNA and mRNA purification Total cellular RNA was isolated using the EZ-RNA kit according to the manufacturer's protocol (Biological industries, Kibbutz Beit Haemek, Israel). RNA pellets were dissolved in nuclease-free sterile water (Amrescot, OH, USA), and their concentrations were determined by the absorbance at 260 nm LevyNissenbaum et al., 2002 LevyNissenbaum et al., , 2003b . Total RNA pooled from 83 normal male or female Caucasians aged 20-60 years, was purchased from Clontecht, Palo Alto, CA, USA (#64106-1, Lot #1070315). The MACS TM mRNA isolation kit was used for mRNA purification. Total RNA preheated for 3 min to 651C was loaded onto MACSt columns type 'm' according to the manufacturer's protocol (Miltenyi Biotec Inc., Auburn, CA, USA). The yield and purity of RNA were assessed by spectrophotometrical measurements at 260 and 280 nm (LevyNissenbaum et al., 2003c) .
TPA treatment
A total of 2 Â 10 6 cells were treated with 7 ml RPMI 1640 medium containing 10% FCS and 12-O-tetradecanoylphorbol-13-acetate (TPA) (Calbiochem, La Jolla, CA, USA) at a concentration of 100 ng/ml (160 nm) for 12, 24, 48 and 72 h (Levy-Nissenbaum et al., 2002).
Fibronectin (FN) treatment
Nontissue culture dishes were coated for 2 h with 3 ml of 20 mg/ ml FN (Biological Industries) at room temperature. Control plates were coated with 3 ml phosphate-buffered saline (PBS). Plates were washed twice with 5 ml of PBS and 2 Â 10 6 cells were plated in 7 ml medium. RNA was isolated from the cells following 24, 48 and 72 h of incubation at 371C .
Southern blot analysis
In total, 4 mg of genomic DNA from eight myeloid leukemia cell lines (CHRF, Dami, KG-1, Meg01, HL-60, U937, THP-1 and K562) and from PBMC derived from three healthy blood bank donors were digested with the endonucleases HindIII and EcoRI as described (Sambrook et al., 1989) . Digested genomic DNA (B4 mg/lane) was separated on a 0.8% agarose gel and transferred onto a nylon membrane. The membrane was hybridized overnight with 32 P-labeled probe (see Northern blot analysis for probe details) at 651C in a shaker, washed with 2 Â SSC, 0.1% sodium dodecyl sulfate (SDS) at room temperature for 10 min, air-dried and exposed to X-OMAT AR film (Eastman Kodak Co, Rochester, NY, USA) at À801C.
Reverse transcription-polymerase chain reaction (RT-PCR) and product sequencing
In total, 2 mg of DNAseI (Ambion, Austin, TX, USA)-treated total RNA samples were used for first-strand cDNA synthesis by means of random hexamer oligonucleotides with 400 U Moloney murine leukemia virus reverse transcriptase (M-MLV RT; Promega, Medison, USA) according to the manufacturer's protocol. The PCR reaction oligonucleotides were as follows: for Pyst1-S: 5 0 -CAA TCT AGA CGG CTC GTG TAG CAG-3 0 ; for Pyst1-AS: 5 0 -TCA CGT AGA TTG CAG AGA GTC CAC CTG -3 0 ; for Pyst2-L-S: 5 0 -CGC GGA TCC CAA GGA CTC CAC CAA CCT GGA C-3 0 ; for Pyst2-L-AS: 5 0 -CCG AAG CTT GTT GGT GGG CGT GGA AAA GTA G-3 0 ; for MKP-4 (Pyst3)-S: 5 0 -GCC TGG ATT CGG AGG GTG CCACAC-3 0 ; for MKP-4 (Pyst3)-AS: 5 0 -CTA GGT GGG GGC CAG CTC GAA GGC GC -3 0 ; for actin-S: 5 0 -GTT TGA GAC CTT CAA CAC CCC-3 0 ; for actin-AS: 5 0 -GTG GCC ATC TCT TGC TCG AAG TC-3 0 . The Pyst1, Pyst2, MKP-4 (Pyst3) and actin amplify a specific cDNA fragment of approximately 700, 500, 600 and 300 base pairs (bp), respectively. PCR was performed in a thermal cycler (PTC-100; MJ Research, Inc., Waltham, MA, USA) using amplification cycles as indicated in the figure legends at an annealing temperature of 601C using BIO-X-ACT TM DNA polymerase (Bioline Inc., Boston, USA). The successful removal of genomic DNA contamination was confirmed in each sample by amplification of the RNA without prior RT reaction. PCR products were visualized on an ethidium bromide 1% agarose gel. The DNA fragments were sequenced and aligned with the corresponding published sequence.
Northern blot analysis
Total RNA (8 mg) samples were size fractionated on 1.2% agarose/formaldehyde gels and capillary transferred onto nitrocellulose membranes, Hybond-N (Amersham International plc, Buckinghamshire, England). After UV crosslinking (Hoefer Pharmacia Biotech Inc., San Francisco, USA), the membranes were prehybridized at 421C for 2 h in a mixture of 50% formamide, 4 Â sodium chloride and sodium citrate (SSC), 5 Â Denhardt solution, 0.2% SDS and 100 mg/ml of preheated denatured sonicated salmon sperm DNA. The cDNA probe, 469 nucleotides (nts) long, was generated by RT-PCR using synthetic oligonucleotide primers designed to amplify the region starting from nt number 615 of the Pyst2-L sequence (GenBank accession no. AF508727). Membranes were hybridized overnight with 32 P-labeled probes at 421C in a shaker, washed with 2 Â SSC, 0.1% SDS at room temperature for 10 min, air-dried and exposed to an X-OMAT AR film (Eastman Kodak Co, Rochester, NY, USA) at À801C. The level of each specific expression was quantified by densitometry and is presented as the ratio between the signal of Pyst2-L mRNA in each cell (or treatment) and the signal of 18 s rRNA in the same cell (or treatment).
SDS-polyacrylamide gel electrophoresis and Western blotting
Total protein was extracted from the indicated cells with Laemmli sample buffer (Sambrook et al., 1989) . These extracts were boiled for 10 min, centrifuged and applied on a miniprotean II system (Bio-Rad) for SDSpolyacrylamide gel electrophoresis using a 10% slab gel as described by Laemmli. Electrophoretic transfer of proteins from the polyacrylamide gel to nitrocellulose (Schleicher and Schull) was performed by a minitransblot electrophoretic cell (Bio-Rad TM ) at 100 V for 1.5 h. After transfer, the nitrocellulose membrane was incubated at room temperature with 3% bovine serum albumin (BSA) in TBS-Tween for 30 min to block free binding sites on the membrane. The blocked nitrocellulose membrane was incubated 2 h at room temperature with rabbit polyclonal antibodies against Pyst2-L and with mouse monoclonal antibodies against GAPDH as previously described (Eshel et al., 2001; Levy-Nissenbaum et al., 2003c) . Erk was detected by rabbit antibodies against Erk1/2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Phosphorylated Erk (p-Erk) was detected by rabbit anti-p-Erk1/2 antibodies (BioSource International, Camarillo, CA, USA). The membranes were than washed three times for 5 min each, with TBSTween buffer, and incubated for 1 h with horseradish peroxidase-conjugated secondary goat antibody against rabbit IgG at room temperature. Finally, the nitrocellulose strips were washed five times for 5 min each with TBS-Tween. The bands were visualized by chemoluminescence-ECL reactions as previously described (Eshel et al., 2001; Levy-Nissenbaum et al., 2003c) .
Flow cytometry
A total of 5 Â 10 5 cells were incubated for 45 min at 41C with the primary antibody (aCD13 and aCD33) (DAKO A/S, Glostrup, Denmark). Antibodies were diluted 1 : 50 in wash medium (RPMI 1640 supplemented with 5% FCS and 0.01% sodium azide). Following the wash, the cells were incubated for 45 min at 41C with the secondary antibody fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA). Following an additional wash, antigen expression on 5000 live cells was determined using a Becton Dickinson FACSort (Mountain View, CA, USA) and the CellQuest software. Baseline staining was obtained by adding wash medium to the cells instead of primary antibody.
Statistics
All results represent the mean7s.d. of at least three different experiments. Data were analysed by Student's t-test, Po0.05 was considered statistically significant.
Results
Pyst2-L is overexpressed in leukocytes from AML patients
In a previous study, cDNA microarrays were employed to identify genes that are more highly expressed in leukemic-phase leukocytes (derived from AML patients prior to treatment) than in remission-phase leukocytes (derived from the same patients following chemotherapy-mediated induction of remission) (Levy-Nissenbaum et al., 2003a) . By analysing such cell pairs from three AML patients, it became clear that each pair from each of these patients exhibited an individual pattern of differentially expressed genes. Genetic diversity and differential responses to chemotherapy may account for such individual gene expression patterns. In order to overcome this 'background noise', which interferes in the identification process of genes whose expression pattern characterizes AML leukocytes, we focused on genes that were more highly expressed by the leukemicphase leukocytes than by the remission-phase leukocytes of all three patients. Pyst2-L (GenBank accession no. AF508727) was one of the two genes that fulfilled this criterion (Groom et al., 1996; Muda et al., 1997; Shin et al., 1997; Dowd et al., 1998) . The cDNA microarray results were confirmed by RT-PCR analysis (Levy-
Pyst2-L mRNA levels were quantified in mononuclear cells present in BM aspirates from seven AML patients obtained at diagnosis. RNA samples from FicollHypaque-separated cells were subjected to Northern blotting using a Pyst2-L-specific probe. This probe was designed to recognize the Pyst2-L transcript specifically (see Materials and methods), as it has a poor homology to the other Pyst family members (i.e. Pyst1 and Pyst3). Figure 1 (left panel) shows that considerably higher levels of the Pyst2-L transcript were present in the RNA samples from these seven patients than by a BM RNA preparation pooled from 83 healthy individuals (middle panel). CD34
þ leukocytes are considered to be the normal ancestors of myeloid leukemia (Geller and Bray, 1997; Moore et al., 2000) . The results shown in Figure 1 (right panel) indicate that the Pyst2-L transcript was not detected in cord blood leukocytes enriched for CD34 þ cells. In all these experiments, the Pyst2-L-expressing THP-1 cell line (see below) served as a positive control. Since BM from healthy individuals is not readily available and in order to verify the finding that the expression of Pyst2-L in normal leukocytes is relatively low, we next determined the expression levels of Pyst2-L in PBMC from healthy blood bank donors. Results of Northern blotting assays show that no Pyst2-L transcript was detected in such cells from 33 out of 34 different healthy blood bank donors (Figure 2 ). Low levels of Pyst2-L were detected in a single sample of PBMC RNA from one blood bank donor (Figure 2 , lane #5). However, it should be noted that Pyst2-L can be detected in some PBMC samples by RT-PCR (LevyNissenbaum et al., 2003b) .
All these results indicate either that the frequency of Pyst2-L-expressing leukocytes in PBMC from leukemia patients is higher than in PBMC from healthy people or that the expression of Pyst2-L per cell is higher in PBMC from leukemia patients than in PBMC from healthy people. These results also support previous ones (Levy-Nissenbaum et al., 2003b) showing that PBMC from healthy individuals enriched for the myeloid markers CD13 or CD33 expressed significantly lower levels of PYST-L than CD13 þ ; CD33 þ leukemia cells. Put together, the results obtained by three different methods, that is, cDNA microarray, Northern blotting and RT-PCR, demonstrated that Pyst2-L is more highly expressed in leukocytes from leukemia patients than in leukocytes from healthy individuals or in leukocytes from AML patients in remission.
Pyst2-L expression by ML cell lines
Leukocytes are heterogeneous cell populations composed of different types of cells at different differentiation and activation states. In view of the possibility that Pyst2-L is selectively expressed in certain leukocyte subpopulations and in order to identify the cell subpopulation expressing high levels of Pyst2-L, we determined the levels of its transcript in the following 10 Pyst2-L is highly expressed in malignancy, differentiating, and activated cells O Levy-Nissenbaum et al myeloid leukemia cell lines. These lines represent, presumably, homogeneous cell populations: CHRF, Dami, KG-1, Meg01, HL-60, U937, THP-1 (AML), PLB680 (promyelocytic leukemia), K562 and KBM5 (chronic myelogenous leukemia). RNA from each of these cell lines was subjected to Northern blot analysis using a Pyst2-L-specific probe. Protein from some of the above cell lines was subjected to Western blot analysis using polyclonal antibodies against Pyst2-L. The Northern ( Figure 3a) and Western blot (Figure 3b ) results show that all the assayed leukemic cell lines express Pyst2-L at varying levels. Additional Northern and Western blotting experiments (data not shown) confirmed the results that certain cell lines express higher levels of Pyst2-L than others. For example, THP-1 cells repeatedly expressed the highest levels of Pyst2-L as compared to other cell lines such as Dami, Meg01 or U937. These results show that leukemic cells express Pyst2-L, whereas normal leukocytes express this phosphatase at much lower levels, if at all. In view of the possibility that the upregulated expression of Pyst2-L in ML cells and in ML cell lines occurred as a result of an aberration within the Pyst2-L DNA, we addressed this issue by Southern blot analysis. The pattern obtained by hybridizing the Pyst2-L probe to genomic DNA from PBMC was compared to the corresponding pattern obtained by hybridizing the Pyst2-L probe to genomic DNA from ML lines (Figure 4) . Since a Pyst2-L band of exactly the same molecular weight was detected in all assayed DNA samples, and since its intensity was similar, it is unlikely that an aberration or an amplification in the Pyst2-L gene occurred in these cells. These results are supported by RT-PCR assays performed with RNA from the THP-1 line. These assays did not reveal any point mutation within the open reading frame (ORF) of Pyst2-L (data not shown). However, an aberration within the regulatory regions of the Pyst2-L gene was not ruled out.
Pyst2-L mRNA levels in other types of malignant cells
We next measured Pyst2-L expression levels in other types of hematological malignancies. RNA was extracted from the following cells: leukemic-phase BM leukocytes derived from two ALL patients; Hodgkin's lymphoma cell lines KM42 and L428; Jurkat, a T-cell lymphoma cell line; and Daudi a B-cell lymphoma cell line. Equal amounts of RNA from these cells were subjected to Northern blotting. Figure 5 shows that leukemic-phase BM cells from the two ALL patients Figure 3 Expression of Pyst2-L by myeloid leukemia cell lines. Equal amounts of total RNA from several ML cell lines and total protein extracts from several ML cell lines and from normal resting T cells were subjected to Northern (upper panel) and Western blotting (lower panel), respectively. Pyst2-L was expressed by every leukemic cell line, both at RNA as well as at the protein level but not by normal resting T cells Figure 4 Southern blot analysis of the Pyst2-L gene in DNA derived from healthy PBMC and from myeloid leukemia cell lines. Equal amounts of DNA from three PBMC and from several ML cell lines were subjected to Southern blotting and hybridized with a Pyst2-L-specific probe (as described in the Materials and methods section). An identical hybridization pattern was seen in DNA extracted from PBMC of healthy individuals as compared to the leukemic cell lines Figure 5 Expression of Pyst2-L by ALL cells and by cell lines derived from various hematological malignancies. Equal amounts of RNA from leukemic BM cells from two ALL patients, from two Hodgkin's tumor lines (KM42 and L428), a T-cell lymphoma (Jurkat) and a B-cell lymphoma (Daudi) were subjected to Northern blotting using a specific Pyst2-L probe. A Pyst2-L transcript was seen by the ALL cells, by one of the Hodgkin's lines and by the Jurkat cells Pyst2-L is highly expressed in malignancy, differentiating, and activated cells O Levy-Nissenbaum et al expressed relatively high levels of Pyst2-L. The results also indicated that whereas the Jurkat and the KM42 cells expressed moderate levels of Pyst2-L, the Daudi and the L428 cells expressed relatively low levels.
In all, 16 nonhematopoietic cancer cell lines (four breast, two melanoma, seven colorectal and three prostate) were screened for Pyst2-L expression. Among the colorectal cancer cell lines were SW480 (primary tumor) and SW620 (a lymph node metastasis of the same colorectal cancer patient). Figure 6 shows that the two melanoma cell lines and two breast cell lines expressed relatively higher Pyst2-L levels than the other cancer cell lines, which expressed low to moderate levels of this molecule. The cells from the metastatic SW620 variant expressed higher levels of the Pyst2-L transcript than cells from the nonmetastatic variant SW480. The Northern analysis shown in Figure 7 indicates that three different lymphoblastoid B-cell lines immortalized in vitro by EBV (Steinitz et al., 1977) express high levels of Pyst2-L. Put together, the above results demonstrate that upregulated levels of Pyst2-L may accompany malignant transformation or immortalization. It should be noted that among the cells assayed, myeloid malignancies express the highest levels of Pyst2-L.
Cellular activation upregulates Pyst2-L expression
As reported above, no Pyst2-L transcript was detected in the vast majority of PBMC from healthy subjects as well as in lymphocyte-enriched fractions from such donors. Since these cells are predominantly resting cells, it was important to find out whether or not activation signals delivered to lymphocytes will affect Pyst2-L expression. Figure 8 (left panel) shows a Northern analysis of RNA from resting peripheral T cells originating in a healthy donor and of the same cells following activation by antibodies directed against CD3 and CD28 supplemented with IL-12 (Romagnani, 1995) . This activation induced a high expression of Pyst2-L in the T cells. In order to see if the increase in Pyst2-L expression is specific to T cells, we compared the expression of this phosphatase in resting and activated endothelial cells. Indeed, activation of HUVEC by IL-1 b and TNF-a brought about an elevation in the Pyst2-L expression level (Figure 8, right panel) . These results indicate that activation of cells from two different lineages (lymphocytes and endothelial cells) is linked to Pyst2-L upregulation. Figure 6 Expression of Pyst2-L by nonhematological malignancies. Equal amounts of RNA from breast cancer cell lines (MB100, MB231, MCF7 and T47D), melanoma cell lines (RK and GT), colon cancer cell lines (0467, 1100, 1203, 427, HT29, SW480 and SW620) and prostate carcinoma cell lines (DU147, 22RV and LNCAP) were subjected to Northern blotting using a Pyst2-L probe. RNA extracted from KMB5 ML cells served as a positive control. Most of the cells expressed low levels of Pyst2-L. The melanoma cell lines and two out of four breast cancer cell lines expressed relatively higher levels of Pyst2-L. The cells from the metastatic SW620 colon carcinoma variant expressed higher levels of the Pyst2-L transcript than cells from the nonmetastatic variant SW480 Figure 7 Expression of Pyst2-L by lymphoblastoid B-cell lines. Equal amounts of RNA from three lymphoblastoid B-cell lines were subjected to Northern blotting using a Pyst2-L probe. Pyst2-L was expressed by these immortalized cells. THP-1 cells served as a positive control Figure 8 Expression of Pyst2-L by normal activated T lymphocytes and by normal activated endothelial cells (HUVEC). Equal amounts of RNA from native PBMC (total PBMC), from activated T cells (by antibodies directed against CD3 and CD28) and from activated HUVEC (by IL-1 b and TNF-a) were subjected to Northern blotting using a Pyst2-L probe. Pyst2-L was expressed by the activated lymphocytes, by the activated HUVEC but not by naive HUVEC or by nonactivated PBMC. THP-1 cells served as a positive control Pyst2-L is highly expressed in malignancy, differentiating, and activated cells O Levy-Nissenbaum et al
MAPK activation signals upregulate Pyst2-L expression in ML cells
Outside-in signals including those mediating stress, malignant transformation, cellular immortalization and cell proliferation are all associated with activation of MAPK signaling cascades (He et al., 1999; Wilkinson and Millar, 2000; Ballif and Blenis, 2001 ). Pyst2-L dephosphorylates in vitro the p42 protein (Erk2) (Dowd et al., 1998 ) and as such is involved in these signaling pathways. In view of the results, reported above, that the Pyst2-L expression is upregulated in malignant cells as well as in cells subjected to immortalization and activation signals, we asked whether a deliberate activation of MAPK would affect Pyst2-L expression in ML cells. To answer this question, we determined, by Northern blotting, the Pyst2-L expression by several ML cell lines treated with known activators of the MAPK signal transduction pathway such as TPA (Koeffler et al., 1981; Chorvath et al., 1983; Hass et al., 1989; Frearson and Alexander, 1996; He et al., 1999; Eckstein, 2000) or FN (Molla and Block, 2000; Mercurius and Morla, 2001 ). Figure 9 shows representative results of Erk1/2 phosphorylation kinetics and of Pyst2-L expression levels in CHRF ML cells treated with TPA. As can be seen, TPA induces Erk1/2 phosphorylation and upregulates both Pyst2-L RNA and protein levels. At the first time point assayed (15 min), a significant increase in Erk1/2 phosphorylation was observed in TPA-treated cells (Figure 9 ). Increased levels of the Pyst2-L transcript were detected in TPA-treated cells already 60 min following the onset of the experiment (Figure 9 ). Whereas Erk-phosphorylation was reduced at later time points, the increase in Pyst2-L transcription continued throughout the entire experiment. The average results obtained in six independent time-course experiments are shown in the legend of Figure 9 . Similar experiments were performed with additional eight leukemic cell lines in 24 independent experiments. A microscopic examination of the cells showed that all TPA-treated cells, harvested 24 h after the initiation of the experiment, manifested the expected differentiation-associated phenotypic changes (Hass et al., 1989) . These included the acquisition of a macrophage-like morphology, cell spreading and adherence to the plastic plates (data not shown). Northern blotting analysis revealed an upregulation of Pyst2-L expression by TPA in all assayed cell lines. For example, Figure 10 shows that Pyst2-L expression by KG-1 cells was significantly upregulated by TPA.
These experiments clearly indicated that the significant TPA-mediated upregulation of Pyst2-L is a general phenomenon at least with respect to ML cells and that the upregulation of Pyst2-L in the TPA-treated cells was associated with the activation of the MAPK pathway. The fact that EBV-mediated immortalization of B cells as well as the activation of endothelial and T cells (Figure 7) , upregulated Pyst2-L expression supports this conclusion as both these types of cellular responses Figure 9 Kinetics of Erk1/2-phosphorylation and Pyst2-L expression. Western and Northern blot analyses. In all, 50 mg of total protein and 6 mg of total RNA obtained from nontreated and from TPA-treated CHRF cells, were subjected to Western and Northern blotting, respectively. The lower panel represents protein levels of Pyst2-L in untreated cells and in cells treated for 48 h with TPA. The results of a representative experiment of four independent experiments are shown. The data below represent the ratio between the density of the Pyst2-L band in the Northern blots of RNA from untreated cells at each indicated time point to that of the Pyst2-L band obtained by blotting RNA from untreated control cells at the onset of the experiment (À). Also shown is the ratio between the density of the Pyst2-L band in the Northern blots of RNA from TPA-treated cells to that of the Pyst2-L band obtained by blotting RNA from untreated control cells at the same time point ( þ ). All the densitometry values were normalized against the density of the 18 s rRNA band.
1 h 6 h 12 h 24 h 48 h 72 h Increased levels of the Pyst2-L transcript were detected in TPA-treated cells already 1 h following the onset of the experiment Pyst2-L is highly expressed in malignancy, differentiating, and activated cells O Levy-Nissenbaum et al involve MAPK signaling pathways (Steinitz et al., 1977; Chu et al., 1996; Babcock et al., 2000) . It should be noted that the expression levels of Pyst2-L were higher in untreated cells cultured for 72 h than in untreated cells cultured for shorter periods. The upregulated expression of Pyst2-L in 72 h cultures might be explained by a growth arrest brought about by the high cell density occurring at this time point. This explanation is supported by the data showing that phosphatases are involved in growth arrest (He et al., 1999; Saxena and Mustelin, 2000; Wilkinson and Millar, 2000; Ballif and Blenis, 2001) . In order to determine whether TPA stimulates only Pyst2-L expression or also that of other Pyst family members, Pyst1 and Pyst3 expression levels were analysed before and after TPA treatment. Initial experiments using RT-PCR (Figure 11 ) demonstrated that in addition to Pyst2, TPA upregulated the expression of both Pyst1 and Pyst3. Figure 11 , however, indicates a different expression pattern of these three phosphatases in normal PBMC. Whereas Pyst2-L is hardly detectable in normal PBMC (see also Figures 3  and 4 and Levy-Nissenbaum et al., 2003b) , the Pyst1 and Pyst2 transcripts are readily detectable. Moreover, whereas THP-1 myelocyte cells express higher levels of Pyst2 than HL-60 promyelocyte and K562 megakaryocyte cells (see also Figure 3a ), the expression of Pyst1 and Pyst3 by the latter cells is higher than that by the THP-1 cells. Hence, the three Pyst family members are not concordantly expressed by normal or leukemic leukocytes.
BM microenvironmental factors, such as FN, play an important role in the proliferation and differentiation of hematopoietic progenitor cells (Weinstein et al., 1989) . In view of the fact that signals mediated by FN involve MAPK activation (Molla and Block, 2000; Mercurius and Morla, 2001), we investigated the effects of FN-mediated signaling on the expression levels of Pyst2-L mRNA in THP-1 cells. Figure 12a shows that culturing THP-1 cells on FN-coated plates significantly upregulated Pyst2-L expression 48 (1.3770.11-fold, Po0.05) and 72 (1.6470.42-fold, Po0.02) h following the onset of the experiment. Pyst2-L upregulation was even more pronounced in the FN-adherent fraction of the cells . These data represent an average of four independent experiments. Panel b of this figure shows that the expression of both Pyst1 and Pyst2-L, but not that of Pyst3, was upregulated by FN. Put together, these experiments indicate that MAPK activation inducers such as TPA and FN upregulated Pyst2-L expression in ML cells. We tentatively conclude that the activation of the MAPK signaling pathway is correlated with an elevation of the Pyst2-L transcript.
In order to establish whether or not there is a cause/ effect relationship between the upregulation of Pyst2-L and MAPK activation, we measured the effect of a specific MAPK inhibitor on the expression level of Pyst2-L. The Mek1/2 PD098059 inhibitor (Dudley et al., 1995) was used in these experiments. Prior to TPA treatment, CHRF ML cells were treated with 10 mm PD098059 for 60 min (TPA þ PD). The following three groups of cells, incubated under the same conditions, were used as controls: untreated cells (NT), TPA-treated cells without PD098059 pretreatment (TPA) and PD098059-pretreated cells in the absence of TPA (PD). Four independent experiments were performed. In each experiment, 3 Â 10 6 cells were harvested at 1, 6, 12 and 24 h following the onset of the experiment. Protein extracted from the cells was subjected to . PCR was performed using 22 amplification cycles for actin and 31 amplification cycles for the other genes. In addition to Pyst2-L, TPA upregulated the expression of both Pyst1 and Pyst3. Whereas Pyst2-L is hardly detectable in normal PBMC, the Pyst1 and Pyst2-L transcripts are readily detectable. Moreover, whereas Pyst2-L is relatively highly expressed by the THP-1 cell line and less so by the HL-60 and K562 cells, the expression of Pyst1 and Pyst3 by the latter cells is higher than that by the THP-1 cells Pyst2-L is highly expressed in malignancy, differentiating, and activated cells O Levy-Nissenbaum et al
Western blotting and developed with specific anti-Erk and antiphospho-Erk antibodies. In parallel, RNA was extracted and subjected to Northern blotting using a Pyst2-L-specific probe. Figure 13 shows the results of one representative experiment. The bars represent an average of four independent experiments. A significant increase in Erk1/2 phosphorylation occurred in TPAtreated cells shortly (1 h) after its addition to the cells. The kinetics of Erk1/2 phosphorylation was similar to that previously reported (Adams and Parker, 1991) . As expected (Dudley et al., 1995) , PD098059 reduced the basal Erk1/2 phosphorylation in treated cells compared to nontreated ones. Furthermore, PD098059 inhibited the TPA-induced Erk1/2 phosphorylation confirming previous results (Rivedal and Opsahl, 2001) . In all, 40-50% of the TPA-induced upregulation of Pyst2-L mRNA was also inhibited by PD098059. Whereas the highest inhibition of the Erk1/2-phosphorylation by this inhibitor was evident 15 min following its addition (data not shown), the inhibition of the TPA-mediated Pyst2-L upregulation was observed only after 6 h following the onset of the experiment (Figure 13 ). This might be due to the differences between the rate of dephosphorylation, which is relatively rapid and may occur in seconds, and the rate of transcription. The fact that the TPAmediated Pyst2-L upregulation was only partially inhibited by the MAPK inhibitor might be explained by at least two nonmutually exclusive possibilities. Firstly, an unidentified molecule or a signaling pathway, in addition to Erk2, might be involved in the induction of this phosphatase. Secondly, the PD098059-mediated inhibition of Erk1/2 phosphorylation occurs earlier than Pyst2-L transcription.
Discussion
DNA microarray analysis indicated that the DUSP Pyst2-L is more highly expressed by leukocytes from leukemia patients in the active stage of the disease than by leukocytes from leukemia patients in remission or by leukocytes from healthy individuals (Levy-Nissenbaum et al., 2003a, b) . The Pyst2-L gene is located on the 3p21 chromosomal region. Aberrations within this area have been previously described to occur in various types of malignancies (Shi et al., 1996; Johnson et al., 2000; Sano et al., 2000) . However, the results presented above showed that no aberration, amplification or point mutations occurred in the Pyst2-L DNA of leukemic cells. It was also indicated, in our previous study, that the Pyst2 gene is transcribed into two transcripts. The longer transcript, Pyst2-L, contains the DUSP catalytic domain, whereas the shorter one, Pyst2-S, does not contain any known phosphatase catalytic domain (Levy-Nissenbaum et al., 2003c) . Northern and Western analyses confirmed, at the mRNA and protein levels, the microarray results. It was conclusively demonstrated that Pyst2-L is significantly higher expressed by malignant hematopoietic cells than by corresponding nonmalignant cells such as unseparated leukocytes from healthy blood bank donors or from leukemia patients in remission. Normal BM or leukocytes from healthy individuals enriched for myeloid or CD34 þ cells expressed either very low levels of Pyst2-L or none at all. Nonhematopoietic cancer cells may also express relatively high levels of Pyst2-L but in the cell series assayed in this study, the expression of Pyst2-L in these cells was in general lower than in ML cells.
There are two distinct, nonmutually exclusive scenarios to explain the overexpression of Pyst2-L in leukemia cells as compared to nonmalignant leukocytes. The first is that the high Pyst2-expressing cells originate in a small subpopulation of nonmalignant Pyst2-expressing progenitor cells. These cells were selectively transformed to malignancy and as a result underwent expansion, thereby dominating the leukocyte population of leukemia patients. Upon remission, this population may be largely eliminated. The second scenario is that transformation-linked processes such as a constitutive MAPK activation induce or at least are associated with an upregulated Pyst2-L expression in the leukemic cells. The results showing that relatively very low levels of Pyst2-L are expressed by normal nontransformed peripheral leukocytes as well as in normal BM are compatible with both scenarios.
The high Pyst2-L expression by leukemic cells, by a variety of ML cell lines and by certain other malignancies (Levy-Nissenbaum et al., 2003a, b) raises the possibility that this phosphatase functions as an oncogene and that its upregulation contributes to malignant transformation. In support of this possibility is the fact that certain regions of the Pyst2-L transcript are homologous with regions of the cdc25 phosphatase (Keyse and Ginsburg, 1993) , which is often overexpressed in various malignancies (Hernandez et al., 1998; Pestell et al., 2000) and is characterized as an oncogene (Nilsson and Hoffmann, 2000) . The fact that chemotherapy-induced remission in AML patients is accompanied by a drastic reduction in Pyst2-L levels (Levy-Nissenbaum et al., 2003a) also supports this possibility. It should, however, be mentioned that many phosphatases including tumor suppressor genes (Galaktionov et al., 1995; Hernandez et al., 1998; Parsons, 1998; Wu et al., 1998; Johnson et al., 2000; Nilsson and Hoffmann, 2000; Pestell et al., 2000) have regions homologous with cdc25. In any case, the PYST2-L phosphatase may be useful as a molecular marker for physiological or pathological cellular activation.
Our data indicate that the MAPK signaling pathway is involved, at least partially in the upregulation of Pyst2-L expression in leukemic cells. This tentative conclusion is supported by two major lines of evidence. First, it was demonstrated that outside-in signals that lead to MAPK activation, concomitantly bring about an increase in Pyst2-L expression. This was the case when activation signals were delivered to endothelial and T cells, when differentiation signals were delivered to leukemic cells and when B cells underwent immortalization by EBV. The second line of evidence supporting the role of MAPK activation in the upregulation of Pyst2-L expression was provided by the experiments demonstrating that a specific MAPK inhibitor also inhibited, partially, Pyst2-L upregulation. The results indicating that outside-in signals leading to MAPK activation are correlated with elevation of Pyst2-L expression exclude the possibility that a clonal expansion alone (see above) is responsible for the high Pyst2-L expression in leukemia (and possibly in other malignant cells). We thus suggest that cell immortalization and/or activation, being hallmarks of malignant transformation, are coupled to, and perhaps require or depend upon an overexpression of Pyst2-L. It is still unclear, however, if the high expression of Pyst2-L in cancer cells is due to the fact that these cells are in a state of constitutive activation, if the regulation of Pyst2-L expression in these cells is aberrant or if the increase in Pyst2-L expression is the result of a failed attempt to counter a constitutively active MAPK cascade in transformed cells.
Phosphatases are pivotal regulators of numerous biochemical processes such as cell cycle control, apoptosis, differentiation and outside-in signaling (Berndt, 1999; Saxena and Mustelin, 2000; Ballif and Blenis, 2001 ). As such, they regulate the expression and activity of a large variety of genes. Phosphatases may downregulate biological processes by dephosphorylating inducer molecules or enhance such processes by removing an inhibitory phosphate from kinases (Biethahn et al., 1999) . Phosphatases such as PP1, PP2A, PP2B, PP2C (Yamamoto et al., 1999; Ofek et al., 2003) , PTPN6 (Beghini et al., 2000) , PTP epsilon C (Tanuma et al., 2000; Andersen et al., 2001) , SHIP (Wagers et al., 1998) and SHP-1 (Horn et al., 2001) were found to be highly expressed in human malignant cells as compared to the corresponding nonmalignant counterparts. In some cases, these enzymes seem to be involved in tumorigenesis and in tumor progression (Parsons, 1998; Gopalakrishna et al., 1999; Yamamoto et al., 1999; Hwang et al., 2001; Poetsch et al., 2001) . It was suggested that certain phosphatases, for example PTPN6, might function as tumor suppressor genes (Parsons, 1998; Dahia, 2000) , whereas other phosphatases such as cdc25A and cdc25B might function as oncogenes (Galaktionov et al., 1995; Wu et al., 1998; Nilsson and Hoffmann, 2000) . Considering the physiological functions of phosphatases and their role in malignancy, together with the results of the present study, lead us to hypothesize that the Pyst2-L phosphatase plays a role in physiological cell activation. The constitutive high expression of Pyst2-L in malignant cells may thus indicate that signal transduction pathways involving Pyst2-L are altered or disrupted in such cells. The fact that TPA-induced Pyst2-L upregulation is only partially inhibited by a specific Mek1/2 inhibitor suggests that the function of Pyst2-L in transformed or activated cells is not restricted to the MAPK signaling cascade.
